Atlas Venture Fund XI, L.P., Ten Percent Owner at Akero Therapeutics, holds 6.56M shares in Dyne Therapeutics (Ticker: DYN), holds 2.75M shares in Xilio Therapeutics (Ticker: XLO), holds 6.01M shares in Day One Biopharmaceuticals (Ticker: DAWN).
What was Atlas Venture Fund XI, L.P.’s latest transaction?
Atlas Venture Fund XI, L.P. latest transaction was an Uninformative Sell of $19.63M.
What was Atlas Venture Fund XI, L.P.'s most profitable transaction?
Atlas Venture Fund XI, L.P.’s most profitable transaction was an Informative Buy of AKRO stock on June 25, 2019. The return on the trade was 39.40%.
What is Atlas Venture Fund XI, L.P.'s role in Akero Therapeutics?
Atlas Venture Fund XI, L.P.'s role in Akero Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.